Literature DB >> 9124430

Chronic heart failure induced by coronary artery ligation in Lewis inbred rats.

Y H Liu1, X P Yang, O Nass, H N Sabbah, E Peterson, O A Carretero.   

Abstract

Rat models of heart failure (HF) secondary to myocardial infarction (MI) are useful in studying the progression of cardiac dysfunction and in testing therapeutic approaches. Sprague-Dawley rats are frequently used; however, this model is hampered by high mortality and a marked variability in infarct size and cardiac dysfunction, necessitating large numbers of rats and prolonged follow-up when studying the progression of dysfunction. In the present work, we developed a model of HF utilizing Lewis inbred rats. Ligation of the left anterior descending coronary artery in Lewis rats produced more uniform and larger infarcts (40 +/- 1.7 vs. 28 +/- 2.3%; P < 0.001) and lower mortality (16 vs. 36%; P < 0.001) than in Sprague-Dawley rats. Using this rat model, we further studied the course of left ventricular (LV) dysfunction and enlargement from 1 wk to 6 mo after MI with cineventriculography. LV end-systolic volume and end-diastolic volume were determined with the area-length method. LV ejection fraction ranged between 0.57 and 0.62 in control rats; after MI, it decreased significantly to 0.48 +/- 0.04 at 1 wk, 0.36 +/- 0.02 at 2 wk, 0.48 +/- 0.02 at 1 mo, 0.35 +/- 0.03 at 2 mo, 0.30 +/- 0.02 at 3 mo, 0.31 +/- 0.02 at 4 mo, and 0.24 +/- 0.02 at 6 mo (P < 0.001, MI vs. sham). LV end-diastolic volume in control rats ranged between 0.32 and 0.42 ml; it increased to 0.48 +/- 0.04 ml at 1 wk, 0.46 +/- 0.02 ml at 2 wk, and 0.46 +/- 0.03 ml at 1 mo. It markedly increased to 0.79 +/- 0.03, 0.79 +/- 0.06, 0.78 +/- 0.03, and 0.80 +/- 0.05 ml at 2, 3, 4, and 6 mo, respectively, after MI (P < 0.001 vs. sham). LV end-diastolic pressure was significantly elevated at all time points. Thus coronary ligation in Lewis inbred rats produces uniformly large infarcts with low mortality, progressive LV dysfunction, and increased LV chamber size. This model may be useful in studying chronic HF secondary to MI.

Entities:  

Mesh:

Year:  1997        PMID: 9124430     DOI: 10.1152/ajpheart.1997.272.2.H722

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  42 in total

1.  Injectable shear-thinning hydrogels used to deliver endothelial progenitor cells, enhance cell engraftment, and improve ischemic myocardium.

Authors:  Ann C Gaffey; Minna H Chen; Chantel M Venkataraman; Alen Trubelja; Christopher B Rodell; Patrick V Dinh; George Hung; John W MacArthur; Renganaden V Soopan; Jason A Burdick; Pavan Atluri
Journal:  J Thorac Cardiovasc Surg       Date:  2015-07-17       Impact factor: 5.209

2.  Delivery of progenitor cells with injectable shear-thinning hydrogel maintains geometry and normalizes strain to stabilize cardiac function after ischemia.

Authors:  Ann C Gaffey; Minna H Chen; Alen Trubelja; Chantel M Venkataraman; Carol W Chen; Jennifer J Chung; Susan Schultz; Chandra M Sehgal; Jason A Burdick; Pavan Atluri
Journal:  J Thorac Cardiovasc Surg       Date:  2018-11-14       Impact factor: 5.209

3.  N-acetyl-seryl-aspartyl-lysyl-proline attenuates renal injury and dysfunction in hypertensive rats with reduced renal mass: council for high blood pressure research.

Authors:  Tang-Dong Liao; Xiao-Ping Yang; Martin D'Ambrosio; Yanlu Zhang; Nour-Eddine Rhaleb; Oscar A Carretero
Journal:  Hypertension       Date:  2009-12-21       Impact factor: 10.190

Review 4.  Practical guidelines for rigor and reproducibility in preclinical and clinical studies on cardioprotection.

Authors:  Hans Erik Bøtker; Derek Hausenloy; Ioanna Andreadou; Salvatore Antonucci; Kerstin Boengler; Sean M Davidson; Soni Deshwal; Yvan Devaux; Fabio Di Lisa; Moises Di Sante; Panagiotis Efentakis; Saveria Femminò; David García-Dorado; Zoltán Giricz; Borja Ibanez; Efstathios Iliodromitis; Nina Kaludercic; Petra Kleinbongard; Markus Neuhäuser; Michel Ovize; Pasquale Pagliaro; Michael Rahbek-Schmidt; Marisol Ruiz-Meana; Klaus-Dieter Schlüter; Rainer Schulz; Andreas Skyschally; Catherine Wilder; Derek M Yellon; Peter Ferdinandy; Gerd Heusch
Journal:  Basic Res Cardiol       Date:  2018-08-17       Impact factor: 17.165

Review 5.  Rodent models of heart failure: an updated review.

Authors:  A C Gomes; I Falcão-Pires; A L Pires; C Brás-Silva; A F Leite-Moreira
Journal:  Heart Fail Rev       Date:  2013-03       Impact factor: 4.214

6.  Tissue-engineered, hydrogel-based endothelial progenitor cell therapy robustly revascularizes ischemic myocardium and preserves ventricular function.

Authors:  Pavan Atluri; Jordan S Miller; Robert J Emery; George Hung; Alen Trubelja; Jeffrey E Cohen; Kelsey Lloyd; Jason Han; Ann C Gaffey; John W MacArthur; Christopher S Chen; Y Joseph Woo
Journal:  J Thorac Cardiovasc Surg       Date:  2014-06-28       Impact factor: 5.209

7.  Effects of angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists in rats with heart failure. Role of kinins and angiotensin II type 2 receptors.

Authors:  Y H Liu; X P Yang; V G Sharov; O Nass; H N Sabbah; E Peterson; O A Carretero
Journal:  J Clin Invest       Date:  1997-04-15       Impact factor: 14.808

8.  Tissue-engineered pro-angiogenic fibroblast scaffold improves myocardial perfusion and function and limits ventricular remodeling after infarction.

Authors:  J Raymond Fitzpatrick; John R Frederick; Ryan C McCormick; David A Harris; Ah-Young Kim; Jeffrey R Muenzer; Alex J Gambogi; Jing Ping Liu; E Carter Paulson; Y Joseph Woo
Journal:  J Thorac Cardiovasc Surg       Date:  2010-04-03       Impact factor: 5.209

9.  Decreased adrenoceptor stimulation in heart failure rats reduces NGF expression by cardiac parasympathetic neurons.

Authors:  Wohaib Hasan; Peter G Smith
Journal:  Auton Neurosci       Date:  2013-12-04       Impact factor: 3.145

10.  Myocardial infarction-induced microRNA-enriched exosomes contribute to cardiac Nrf2 dysregulation in chronic heart failure.

Authors:  Changhai Tian; Lie Gao; Matthew C Zimmerman; Irving H Zucker
Journal:  Am J Physiol Heart Circ Physiol       Date:  2018-01-26       Impact factor: 4.733

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.